{"id":842508,"date":"2025-04-28T08:46:26","date_gmt":"2025-04-28T12:46:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/"},"modified":"2025-04-28T08:46:26","modified_gmt":"2025-04-28T12:46:26","slug":"silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/","title":{"rendered":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug"},"content":{"rendered":"
\n

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer\u2019s disease (AD) exclusively licensed to Silo Pharma from Columbia University.\u00a0<\/p>\n

The patent, titled \u201cCompositions and Methods for the Treatment of Alzheimer\u2019s Disease and Other Neurogenerative Disease,\u201d covers SPC-14\u2019s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD.\u00a0By targeting the two receptor molecules, the drug has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety).<\/p>\n

\u201cEarly pre-clinical studies of SPC-14 have demonstrated the drug\u2019s potential to improve and restore cognitive memory function,\u201d said Eric Weisblum, CEO of Silo. \u201cThe patent application for SPC-14 supports our intellectual property strategy for strong security and protection of each of our drug platforms.\u201d<\/p>\n

SPC-14 was developed under a sponsored research agreement with Columbia University.\u00a0In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize the drug SPC-14.<\/p>\n

\n About SPC-14<\/strong>
\n
SPC-14 is a\u00a0novel therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer\u2019s disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety.<\/p>\n

\n About Silo Pharma<\/strong>
\n
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease and multiple sclerosis. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0silopharma.com<\/a><\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This news release contains “forward-looking statements” within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n

\n Contact<\/strong>
\n
800-705-0120
investors@silopharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer\u2019s disease (AD) exclusively licensed to Silo Pharma from Columbia University.\u00a0 The patent, titled \u201cCompositions and Methods for the Treatment of Alzheimer\u2019s Disease and Other Neurogenerative Disease,\u201d covers SPC-14\u2019s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD.\u00a0By targeting the two receptor molecules, the drug has shown efficacy against luteinizing … <\/p>\n

Continue reading “Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-842508","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer\u2019s disease (AD) exclusively licensed to Silo Pharma from Columbia University.\u00a0 The patent, titled \u201cCompositions and Methods for the Treatment of Alzheimer\u2019s Disease and Other Neurogenerative Disease,\u201d covers SPC-14\u2019s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD.\u00a0By targeting the two receptor molecules, the drug has shown efficacy against luteinizing … Continue reading "Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-28T12:46:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug\",\"datePublished\":\"2025-04-28T12:46:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/\"},\"wordCount\":574,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/\",\"name\":\"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==\",\"datePublished\":\"2025-04-28T12:46:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk","og_description":"SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer\u2019s disease (AD) exclusively licensed to Silo Pharma from Columbia University.\u00a0 The patent, titled \u201cCompositions and Methods for the Treatment of Alzheimer\u2019s Disease and Other Neurogenerative Disease,\u201d covers SPC-14\u2019s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD.\u00a0By targeting the two receptor molecules, the drug has shown efficacy against luteinizing … Continue reading \"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-28T12:46:26+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug","datePublished":"2025-04-28T12:46:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/"},"wordCount":574,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/","name":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==","datePublished":"2025-04-28T12:46:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQzOTcyMCM2OTA3NTgwIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-expands-intellectual-property-portfolio-with-patent-application-for-exclusively-licensed-alzheimers-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer\u2019s Drug"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=842508"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/842508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=842508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=842508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=842508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}